Gainers

• Bullfrog AI Hldgs (NASDAQ:BFRG) stock rose 17.5% to $1.41 during Thursday's after-market session. The market value of their outstanding shares is at $20.5 million.
• Century Therapeutics (NASDAQ:IPSC) shares moved upwards by 10.06% to $2.34. The market value of their outstanding shares is at $393.5 million.
• Processa Pharma (NASDAQ:PCSA) shares rose 9.74% to $3.04. The company's market cap stands at $6.9 million.
• Profusa (NASDAQ:PFSA) shares rose 9.49% to $0.83.
• CytoMed Therapeutics (NASDAQ:GDTC) shares moved upwards by 9.18% to $1.07. The market value of their outstanding shares is at $12.0 million.
• Jasper Therapeutics (NASDAQ:JSPR) shares rose 7.48% to $0.74. The market value of their outstanding shares is at $22.3 million. As per the press release, Q4 earnings came out 3 days ago.

Losers

• IO Biotech (NASDAQ:IOBT) stock decreased by 16.7% to $0.03 during Thursday's after-market session. The market value of their outstanding shares is at $3.1 million.
• IM Cannabis (NASDAQ:IMCC) stock decreased by 10.15% to $0.3. The market value of their outstanding shares is at $1.7 million. The company's, Q4 earnings came out 2 days ago.
• OSR Holdings (NASDAQ:OSRH) shares fell 9.77% to $0.5. The market value of their outstanding shares is at $15.0 million. As per the press release, Q4 earnings came out 2 days ago.
• NuCana (NASDAQ:NCNA) stock declined by 7.45% to $1.51. The company's market cap stands at $587.6 million.
• Tivic Health Systems (NASDAQ:TIVC) stock decreased by 6.93% to $0.93. The company's market cap stands at $1.7 million.
• CDT Equity (NASDAQ:CDT) shares declined by 6.84% to $3.68. The market value of their outstanding shares is at $24.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.